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A B S T R A C T
Small bowel capsule endoscopy (CE) is a simple, safe, non-invasive, reliable technique, 
well accepted and tolerated by the patients, which allows complete exploration of the 
small intestine. The advent of CE in 2000 has dramatically changed the diagnosis and 
management of many diseases of the small intestine, such as obscure gastrointestinal 
bleeding, Crohn’s disease, small bowel tumors, polyposis syndromes, etc. Capsule en-
doscopy has become the gold standard for the diagnosis of most diseases of the small 
bowel. Lately this technique has also been used for esophageal and colonic diseases. 
The present review focuses on the indications, limitations and diagnostic yield of cap-
sule endoscopy in the investigation of small bowel diseases.
I N T R O D U C T I O N
Until a few years ago, the small bowel was an organ which was very difficult to 
explore with the available endoscopic, radiological and nuclear medicine techniques. In 
routine practice, only the last few centimeters of the ileum were accessible to retrograde 
visualization by ileocolonoscopy. Exploration from the proximal side by push, sonde 
or intraoperative enteroscopy were invasive procedures that did not always allow us 
to visualize the lesions in the small bowel.1 Sonde enteroscopy had been abandoned 
in the 90’s because it was a tedious technique (long duration of the procedure) and it 
had several technical limitations. Push enteroscopy is limited by the depth of insertion 
of the scope and is poorly tolerated. Intraoperative enteroscopy is the most effective 
of these techniques, but it is the most invasive with a significant percentage of adverse 
side effects.2 Single and double balloon enteroscopy, as well as spiral enteroscopy have 
also been introduced in recent years; however, they are time consuming and techni-
cally demanding and have not been incorporated in every day clinical practice as yet.2 
With wireless capsule endoscopy (CE) we can provide a simple, safe, non-invasive, 
reliable procedure, well accepted and tolerated by the patient, which has revolution-
ized the study of the small bowel. This technique evaluates endoscopically, with high 
resolution images, the whole small bowel, avoiding any sedation, surgery or radiation 
exposure.2
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T e C h N I C A l  p R O p e R T I e S
The capsule endoscope is a disposable, small, swallowable, 
wireless, miniature camera which allows us to get a direct visu-
alization of the gastrointestinal mucosa.3 The initial endoscopy 
capsule was developed by Given Imaging (Yoqneam, Israel) 
and approved in Europe by the European Medicines Agency 
and in the United States by the Food and Drug Administra-
tion in 2001.3 To date this technique is available in over 4500 
gastrointestinal centers throughout the world.
The capsule measures only 11 mm × 26 mm and weighs 
3.7 g, holds a metal oxide semiconductor imaging-chip video 
camera, 6 white light-emitting diode illumination sources, 2 
silver-oxide batteries and a radio telemetry transmitter. The 
image filed is 140 degrees, magnification is × 8 and the depth 
of view is 1 to 30 mm.4,5
Before the capsule is swallowed, 8 skin antennas are taped 
to the patient’s anterior abdominal wall and connected to the 
hard drive. After an overnight fast and a bowel preparation 
with 2 liters of polythylene electrolyte solution, the patient 
swallows the capsule with a few sips of water, then the capsule 
is passively moved along by peristalsis.6 Two hours after inges-
tion, the patient is allowed to drink, while eating is allowed 
after 4 hours. During the procedure the patient may carry on 
with his/her daily activities.
The camera is activated by removal of the capsule from its 
magnetic holder and takes 2 images per second and transmits 
these by means of radio frequency to a sensor array placed on 
the patient’s abdomen and from there to a recording device 
in a belt that the patient wears for the duration of the battery 
life (8 hours). The use of the real time viewer may shorten 
the procedure, as the patient can be disconnected once the 
cecum is visualized.5 
After 8 hours, the sensor array and recorded data are 
removed and the recorded images are downloaded to the 
computer. The capsule is excreted with the feces, usually within 
24 to 48 hours.7 It takes on average 40-60 min for a trained 
gastroenterologist to read the images downloaded and one of 
the limitations of the test is the fact that it is time-consuming.8,9 
Since its development, additional support systems have been 
added to the software to assist the reader, such as localization 
capability, suspected blood indicator, a multiviewing feature 
and quick view modality.3
l I m I T A T I O N S  O f  S m A l l  B O w e l 
C A p S U l e  e N D O S C O p y  ( T A B l e  1 ) 
The retention of the endoscopy capsule is the main com-
plication of the procedure and is defined when the device 
remains in the digestive tract for a minimum of 2 weeks.10 The 
frequency of this problem varies, depending mostly on the clini-
cal indication for CE and ranges from 0% in healthy subjects, 
to 1.5% in patients with obscure gastrointestinal bleeding, to 
5% in patients with suspected Crohn’s disease and to 21% in 
patients with intestinal obstruction.3 Patency capsule or small 
bowel follow through should be performed before small bowel 
capsule endoscopy in patients in whom intestinal obstruction 
is suspected. This should be particularly sought in patients 
with Crohn’s disease.6 In patients in whom patency capsule 
precedes the Pillcam examination, the cost is increased by 
approximately 30%. At present CE has some technical limi-
tations; it cannot be used to obtain biopsy specimens or for 
endoscopic treatment and it cannot be controlled remotely.8 
Capsule endoscopy has also some clinical limitations which are 
problems in sizing and locating small bowel lesions,2 a possible 
false-negative CE result, due to the fact that the global miss 
rate is about 11%, ranging from 0.5% for ulcerative lesions to 
18.9% for neoplastic disease and the fact that sometimes we 
can get findings of uncertain relevance in healthy subjects.8 






•	Celiac disease and other malabsorptive syndromes
•	Drug enteropathies (e.g. NSAID)
•	Small bowel polyposis syndromes 
•	HIV patients with gastrointestinal symptoms
•	Henoch-Schonlein purpura
•	Patients with small bowel transplants and with intestinal 
graft versus host disease (monitoring the response to im-
munosuppressive therapy)
limitations
•	Retention of endoscopy capsule
•	May miss lesions 
•	Technical limitations 
- unable to obtain biopsy specimens 
- cannot deliver endoscopic treatment (e.g. drugs or he-
mostasis) 
- cannot be controlled or maneuvered remotely
- limited battery life
•	Cost
HIV = human immunodeficiency virus; NSAID = non-steroidal anti-
inflammatory drugs
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Another drawback is that in almost 20% of procedures the 
capsule does not reach the cecum while it is active, due to the 
8 hour life span of its battery.9
I N D I C A T I O N S  O f  S m A l l  B O w e l 
C A p S U l e  e N D O S C O p y  ( T A B l e  1 )
Currently, CE is recommended as a third stage examina-
tion, after negative gastroscopy and colonoscopy in patients 
with obscure gastrointestinal bleeding.11-14 Also many studies 
have established, with a growing body of evidence, that this 
technique is cost-effective in other clinical situations, such as 
detection of small bowel lesions in Crohn’s disease in patients 
in which other methods have failed to provide a diagnosis, 
non steroidal anti-inflammatory drug enteropathies, celiac 
disease, small bowel polyposis syndromes and small bowel 
tumors.11-14 Other possible indications are HIV patients with 
gastrointestinal symptoms, malabsorptive syndromes other 
than celiac disease, Henoch-Schonlein purpura, patients with 
small bowel transplants and with intestinal graft versus host 
disease, particularly in monitoring the response to immuno-
suppressive therapy.11-14
D I A g N O S T I C  y I e l D
With regards to the main indication of small bowel capsule 
endoscopy, i.e. bleeding of obscure origin, this is defined as 
bleeding of unknown origin that persists or recurs (i.e. recur-
rent or persistent iron deficiency anemia, fecal occult blood test 
positivity or visible bleeding) after a negative initial workout 
including gastroscopy, colonoscopy, small bowel barium follow 
through or enteroclysis and push enteroscopy.15 Bleeding of 
obscure origin is further subdivided in two clinical entities: i) 
Obscure – occult, as manifested by recurrent iron-deficiency 
anemia and/or recurrent positive fecal occult blood test results, 
ii) Obscure – overt, with recurrent passage of visible blood 
(hematochezia / melena).15 Management of patients with gas-
trointestinal bleeding of obscure origin remains a challenging 
problem in clinical practice. When a bleeding source is not 
identified in upper or lower gastrointestinal endoscopy, the 
small bowel is interrogated and wireless capsule endoscopy 
has become the method of choice for this purpose. Indeed, 
the diagnostic yield of CE has been demonstrated in a number 
of comparative studies, which show that capsule endoscopy is 
superior to push enteroscopy (50% vs 24%)16 barium follow 
through (31% vs 5%), computed tomography enteroclysis (59% 
vs 36%),17 intraoperative enteroscopy (74.4% vs 68%),18 double 
balloon enteroscopy (59% vs 42%)19 and angiography (72% 
vs 56%).20 However, it should be noted that not only in the 
above mentioned studies, but in many other publications, the 
diagnostic yield of CE in patients with obscure bleeding varies 
considerably. These immense variations among reports clearly 
reflect differences in image interpretation, since a consensus 
on what represents a positive finding has not been reached 
as yet. According to a classification proposed by our group,21 
findings are considered positive if they are the actual source of 
bleeding, while lesions suspected to be the source are classified 
as findings of uncertain significance. Using the strict criteria 
adopted in our classification, we reported a diagnostic yield 
of 41.6% for positive findings in patients subjected to capsule 
endoscopy for the investigation of obscure gastrointestinal 
bleeding.21 
Regarding the other major indication for capsule endos-
copy, i.e. patients with suspected or diagnosed Crohn’s disease 
and given the numerous small studies involving CE and the 
difficulty in quantifying the diagnostic yield of CE from these 
studies, a meta-analysis was undertaken by Triester et al.22 A 
literature search analyzed prospective trials comparing CE 
to alternative diagnostic modalities to detect lesions beyond 
the reach of standard upper endoscopy and colonoscopy (not 
including ileoscopy). A total of 11 trials involving 309 patients 
were included in the meta-analysis. All trials excluded pa-
tients with known strictures. All patients served as their own 
controls between imaging studies. In the comparison of CE 
with small bowel barium radiography, the “diagnostic yield” 
of CE for findings in all patients consistent with a diagnosis of 
Crohn’s disease was 64% versus 24% for barium radiography 
for an “incremental yield” of 40%. The incremental yield 
was greater (46%) in patients being evaluated for suspected 
recurrent Crohn’s disease. In the comparison of CE with 
colonoscopy and ileoscopy, CE had a 61% yield for Crohn’s 
disease in all patients compared to a 46% yield for ileoscopy 
(incremental yield = 15%). Similarly, the incremental yield 
(26%) was greater in the established Crohn’s disease subset. 
In the comparison of CE with computed tomography (CT) 
enterography/enteroclysis, CE had a 69% yield versus 30% 
for CT with an incremental yield of 39%. The conclusion of 
the study was that CE did not reveal a statistically significant 
greater yield of findings (compared to any other modality) in 
patients with suspected Crohn’s disease, but it did identify a 
greater number of lesions than all alternative modalities in 
patients with established Crohn’s disease. 
Small bowel capsule endoscopy is also helpful in celiac 
disease patients in select situations. It can be performed in 
patients who are unable or unwilling to undergo conventional 
endoscopy, those with positive celiac serology with normal 
duodenal biopsies and those who do not respond to gluten-free 
diet or develop alarm symptoms.23 
C O N C l U S I O N  A N D  f U T U R e 
D I R e C T I O N S
Today, small bowel capsule endoscopy is a valuable tool in 
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the diagnostic management of patients with obscure gastroin-
testinal bleeding, as well as those with suspected or diagnosed 
Crohn’s disease. In the future CE may be used to determine 
medical response to therapy, while new capsules might be able 
to provide tissue for histological examination in addition to 
improved views and extended battery life for visualization of 
the entire small intestine.24 
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